RPAM
PBYI icon

Rhenman & Partners Asset Management’s Puma Biotechnology PBYI Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$4.94M – 96
2017
Q4 		$4.94M Buy
+50,000
New +$5.6M 0.67% 55

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Rhenman & Partners Asset Management's PBYI Position: Q1 2018 in Review

Rhenman & Partners Asset Management sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 50,000 shares — an estimated $4.94M sold.

Rhenman & Partners Asset Management first reported a position in PBYI in Q4 2017 and held it in 1 quarter. The position peaked at $4.94M in Q4 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Rhenman & Partners Asset Management reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 50,000 Puma Biotechnology shares in Q1 2018, an estimated $4.94M.
  • Rhenman & Partners Asset Management first reported a position in Puma Biotechnology in Q4 2017 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Puma Biotechnology position peaked at $4.94M in Q4 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.